Stocks · Health care · Pharmaceutical Preparations

Johnson & Johnson

JNJ Clue Score64
United States Fiscal year ends January CIK 0000200406 Results filed 13 Oct 2026

What the insiders did No buying or selling

By person

13 insiders · 0 transactions
52.6×

J. Duato holds 52.6 times base salary in stock. $84.30M of shares against $1.60M in salary for 2025.

Salary from the company's own proxy. The shares are what J. Duato last reported holding, valued at $274.74, the price Common Stock was last bought or sold at on the open market here, on 2 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Joaquin Duato
CEO and Chairman of the Board
—
—
—
306,819
$84.30M
−15.5%
Jennifer L Taubert
EVP, WWC. Innovative Medicine
—
—
—
194,451
$53.42M
+25.6%
Kathryn E Wengel
EVP, Chief TO and Risk Officer
—
—
—
114,288
$31.40M
+38.9%
Timothy Schmid
EVP, WW Chair, MedTech
—
—
—
26,251
$7.21M
+89.6%
James D. Swanson
EVP, CIO
—
—
—
25,698
$7.06M
+76.3%
John C Reed
EVP, Innovative Medicine, R&D
—
—
—
24,911
$6.84M
+70.9%
Robert J Decker
VP Corporate Controller
—
—
—
23,682
$6.51M
+24.8%
Vanessa Broadhurst
EVP, Global Corp Affairs
—
—
—
23,003
$6.32M
+16.0%
Kristen Mulholland
EVP, Chief HR Officer
—
—
—
19,830
$5.45M
+69.6%
Elizabeth Forminard
EVP, Chief Legal Officer
—
—
—
16,994
$4.67M
+103.8%
Joseph J Wolk
Exec VP, CFO
—
—
—
14,000
$3.85M
—
John G Morikis
Director
—
—
—
1,849
$507.86K
+208.9%
Mark A Weinberger
Director
—
—
—
1,000
$274.74K
—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.